OOIR: Observatory of International Research

Papers

(The H4-Index of Hepatology is 78. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Reply: Fiber and whole grain intakes in relation to liver cancer risk—An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies	2148
Requirement of RORα for maintenance and antitumor immunity of liver‐resident natural killer cells/ILC1s	1848
Stellate cell-specific adhesion molecule protocadherin 7 regulates sinusoidal contraction	1660
Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis	1134
Letter to the Editor: Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury	441
Reply: Medications promoting abstinence in alcohol-associated cirrhosis	317
Late-Breaking Abstracts	262
Post-vax vein vigilance: Unmasking splanchnic thrombosis risks	236
Boosting Success: Optimizing Thiopurine Therapy in Autoimmune Hepatitis With Allopurinol	234
Letter to the editor: Beneath the surface of the pandemic: Persons with alcohol‐associated liver disease need our attention	226
Letter to the Editor: The Hepa 1–6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy	226
Cover Image	226
Alan Hofmann (1931‐2021): A career well spent understanding bile acids	205
Retracted: M2 Macrophage–Derived Exosomes Facilitate HCC Metastasis by Transferring αMβ2 Integrin to Tumor Cells	197
Letter to the editor: Treatment options for 3–5‐cm solitary HCC—Need a closer look!	190
Letter to the editor: The precise relationship between MELD and survival without a liver transplant	186
Letter to the editor: The role of aquaporin 9 in modeling of ornithine transcarbamylase deficiency	183
Changing epidemiology of hepatocellular cancer in the United States: Winning the battle but it is not over yet	182
Biopsy-free endpoints in MASH trials: A comparative look at MASHResInd and FAST	181
Retraction: GABA induces the differentiation of small into large cholangiocytes by activation of Ca2+/CaMK I-dependent adenylyl cyclase 8	179
Reply: Liver stiffness progression comparison between diabetics and non-diabetics with biopsy-proven metabolic dysfunction–associated steatosis	167
Honey, I shrunk the tumor: Downstaging HCC before liver transplantation	159
Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals	150
Implementation of a controlled human infection model for evaluation of HCV vaccine candidates	150
Reply	145

Reply: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?	144
Moving beyond the liver—Proteomics as a molecular footprint of systemic damage in metabolic dysfunction–associated steatotic liver disease	141
Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis	141
NOD‐like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH	133
Higher level of HBsAg associated with delayed development of HCC in immune-tolerant patients	126
PGD2/DP1 axis promotes liver regeneration by secreting Wnt2 in KCs in mice	123
Letter to the Editor: Assessing HCC incidence and surveillance thresholds in non-cirrhotic MASLD	120
More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC	119
Multi-omics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma	118
Letter to the Editor: Real-world evidence supports nephrotoxic risk of anakinra plus zinc in alcohol-associated hepatitis	116
Hepatic encephalopathy—We are no longer those who believe that reality is what we perceive	116
Efficacy and safety of infliximab in patients with autoimmune hepatitis	115
ZNT1 and Zn2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor	115
Switch‐associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1	114
Acute encephalopathy without hyperammonemia has a different presentation than overt HE and displays a similarly severe prognosis	112
Plasma proteomic signature of fatty liver disease: The Rotterdam Study	104
Hepatocyte‐specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin‐like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice	104
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study	104
Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death	100
Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma	100
Access to technology to support telehealth in areas without specialty care for liver disease	99
Regulatory role and translational potential of CCL11 in liver fibrosis	98
Letter to the Editor: LO2, a misidentified cell line: Some data should be interpreted with caution	98
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease	96
Comparison of pharmacological therapies in metabolic dysfunction–associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis	96
	95
Letter to the Editor: Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma	93
Letter to the Editor: Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content—Systematic review and network meta-analysis	92
Genes that fit just right: Unzipping the genome of fatty liver disease	92
Letter to the Editor: Primary sclerosing cholangitis and autoimmune hepatitis—Distinct or common autoimmune penetrance?	91
Reply	91
Therapeutic manipulation of the microbiome in liver disease	91
Reply: Is fecal acetate a viable pan-etiological predictor of outcomes in HCC immunotherapy?	91
Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatm	91
Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis	90
The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: A post hoc analysis	90
Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma	89
Reply: The CRAPT-M score: Robust enough for clinical practice?	87
Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries’ framework for digital twin advancement	87
Erratum: Effects of trientine and penicillamine on intestinal copper uptake: A mechanistic 64Cu PET/CT study in healthy humans	87
	87
Reply: Several issues to consider in the study of hepatocellular carcinoma progression mechanism	85
Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study	84
Use of noninvasive scores to predict hepatic steatosis: Flaws and caveats	83
The spectrum of primary liver cancers: heterogeneity and continuity. A foundation for diagnosis and treatment of cancer	83
Solving the puzzle of fibrosis resolution in alcohol-associated liver disease: An insight from KDM5 demethylases and LXR activation	82
Understanding advanced cystic fibrosis liver disease through genetic variation: Where do the pathways lead and how much further must we go?	82
Reply: How does bile acid–induced IRF3 phosphorylation mediate cholestatic liver and kidney injury?—More needs to be known	81
Erratum: Identification and characterization of a hepatic IL-13–producing ILC3-like population potentially involved in liver fibrosis	81
Letter to the Editor: Overlooking the important factor: Hypoxia	81

Letter to the editor	80
The digital determinants of liver disease	79
5S rRNA pseudogene transcripts are associated with interferon production and inflammatory responses in alcohol-associated hepatitis	78
Instructions to Authors	78